Algert Global LLC Increases Stock Position in Phreesia, Inc. $PHR

Key Points

• Algert Global LLC increased its stake in Phreesia, Inc. by 101.3% in the first quarter, acquiring an additional 78,810 shares to hold a total of 156,643 shares valued at approximately $4.0 million.
• Institutional investors and hedge funds now own 92.10% of Phreesia's stock, indicating a significant level of interest and investment from major financial players.
• Phreesia reported a revenue of $115.94 million for its most recent quarter and surpassed analysts' estimates, highlighting its growing presence in the healthcare IT sector.

Algert Global LLC raised its holdings in Phreesia, Inc. (NYSE:PHR - Free Report) by 101.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 156,643 shares of the company's stock after purchasing an additional 78,810 shares during the period. Algert Global LLC owned 0.27% of Phreesia worth $4,004,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of PHR. Johnson Financial Group Inc. lifted its holdings in shares of Phreesia by 381.3% in the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company's stock valued at $28,000 after purchasing an additional 896 shares in the last quarter. Quarry LP lifted its holdings in shares of Phreesia by 210.9% in the fourth quarter. Quarry LP now owns 2,835 shares of the company's stock valued at $71,000 after purchasing an additional 1,923 shares in the last quarter. KBC Group NV purchased a new stake in shares of Phreesia in the first quarter valued at about $74,000. CWM LLC lifted its stake in shares of Phreesia by 994.9% during the first quarter. CWM LLC now owns 4,040 shares of the company's stock valued at $103,000 after buying an additional 3,671 shares during the period. Finally, NewEdge Advisors LLC lifted its stake in shares of Phreesia by 12.1% during the fourth quarter. NewEdge Advisors LLC now owns 4,256 shares of the company's stock valued at $107,000 after buying an additional 459 shares during the period. Hedge funds and other institutional investors own 92.10% of the company's stock.

Insider Buying and Selling

In other news, General Counsel Allison C. Hoffman sold 1,245 shares of the stock in a transaction on Thursday, July 17th. The shares were sold at an average price of $26.89, for a total value of $33,478.05. Following the completion of the sale, the general counsel owned 136,978 shares of the company's stock, valued at $3,683,338.42. This represents a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Evan Roberts sold 1,892 shares of the stock in a transaction on Thursday, July 17th. The stock was sold at an average price of $26.89, for a total transaction of $50,875.88. Following the completion of the sale, the chief operating officer directly owned 772,915 shares of the company's stock, valued at $20,783,684.35. The trade was a 0.24% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 53,882 shares of company stock valued at $1,513,007. 5.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. DA Davidson raised shares of Phreesia to a "strong-buy" rating in a research note on Tuesday, July 22nd. KeyCorp upped their price objective on shares of Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a research note on Monday, July 14th. Wall Street Zen raised shares of Phreesia from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. Canaccord Genuity Group reduced their price objective on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating on the stock in a research note on Thursday, May 29th. Finally, Citigroup reaffirmed a "buy" rating on shares of Phreesia in a research report on Wednesday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $32.27.

Phreesia Trading Up 2.1%

PHR stock traded up $0.61 on Monday, hitting $30.36. 1,048,008 shares of the company were exchanged, compared to its average volume of 593,822. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $31.04. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.95 and a quick ratio of 1.95. The business's fifty day moving average is $27.58 and its two-hundred day moving average is $26.40. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -41.03 and a beta of 0.71.

Phreesia (NYSE:PHR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 28th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.06. Phreesia had a negative net margin of 9.83% and a negative return on equity of 16.23%. The firm had revenue of $115.94 million during the quarter, compared to analyst estimates of $115.00 million. During the same quarter in the prior year, the business posted ($0.05) earnings per share. Phreesia's revenue for the quarter was up 14.5% compared to the same quarter last year. Phreesia has set its FY 2026 guidance at EPS. As a group, research analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current year.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.